Content Block Tag: COVID-19

‘COVID Vaccine Statement’ of page ‘COVID-19’

(Updated 2/23/2021) NRG Oncology Pharmacy Subcommittee: COVID-19 Vaccination COVID-19 Vaccine Recommendation: NRG Oncology defers to local institutional guidelines. In the absence of institutional guidelines, NRG Oncology recommends following current clinical practice guidelines from ASCO, ACS or NCCN. There are not specific contraindications to receiving COVID-19 vaccine on current NRG Oncology studies. Clinical Resources: https://www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/low-blood-counts/infections/covid-19-vaccines-in-people-with-cancer.html https://www.asco.org/asco-coronavirus-resources/covid-19-patient-care-information/covid-19-vaccine-patients-cancer https://share.upmc.com/2019/01/flu-vaccine-during-chemo/#:~:text=The%20American%20Cancer%20Society%20(ACS,cell%20or%20bone%20marrow%20transplant. […]

‘Text/HTML’ of page ‘COVID-19’

COVID-19 Updates

‘For our NRG Oncology Member Sites’ of page ‘COVID-19’

(Updated 2/11/2021) NRG Oncology remains committed to supporting your research efforts, whatever that may look like at your institution today. While the pandemic is commanding time, energy, and resources across the country and the world right now, the conduct of clinical research is a long-term commitment.  Together, we will weather this storm and do our best for […]

‘For Patients’ of page ‘COVID-19’

(Updated 3/23/2020) We understand that as a patient or family member of a patient participating in – or considering participating in, a research study may have questions related to your care and/or ability to complete the requirements of the research study given the current pandemic.  See also the information linked below for cancer patients from the National Cancer Institute. Medical facilities […]

‘For Patients’ of page ‘COVID-19’

‘Guidance Memos & NRG Leadership Updates’ of page ‘COVID-19’

Update to Reporting of COVID-19 Minor Deviations for NRG Oncology Studies (6/30/2022) General Information on Potential Drug Interactions of Concomitant CTEP IND Agents and the SARS-CoV-2 Antiviral Drug PAXLOVID  (3/3/2022) NRG Oncology COVID-19 Vaccine Statement  (2/23/2021)  Updated Message from NRG Oncology Leadership (12/15/2020)  Guidance for Shipment of CTEP Oral IND Agents  (4/30/2021) Resumption of Biospecimen Submissions for […]